Title
Intravitreal bevacizumab in diabetic retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 knobloch lecture
Date Issued
01 January 2018
Access level
open access
Resource Type
review
Author(s)
Arevalo J.F.
Liu T.Y.A.
Wu L.
Lasave A.F.
Farah M.
Maia M.
Penha F.M.
Rodrigues E.B.
Morales-Canton V.
Fromow-Guerra J.
Guerrero-Naranjo J.L.
Dalma-Weiszhausz J.
Velez-Montoya R.
Quiroz-Mercado H.
Rodriguez F.J.
Gomez F.E.
Brieke A.C.
Goveto A.
Berrocal M.H.
Cruz-Villegas V.
Graue-Wiechers F.
Lozano-Rechy D.
Fulda-Graue E.
Hernández A.
Saravia M.J.
Schlaen A.
Rojas J.
Ingolotti M.
Avila M.
Carla L.
Cardillo J.
Jorge R.
Carpentier C.
Verdaguer J.
Verdaguer J.I.
Sepúlveda G.
Alezzandrini A.
Garcia B.
Zas M.
Gallego-Pinazo R.
Diaz-Llopis M.
Dolz-Marco R.
Figueroa M.
Contreras I.
Ruiz-Casas D.
Publisher(s)
Asia-Pacific Academy of Ophthalmology
Abstract
The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy.
Start page
36
End page
39
Volume
7
Issue
1
Language
English
OCDE Knowledge area
Endocrinología, Metabolismo (incluyendo diabetes, hormonas)
Oftalmología
Subjects
Scopus EID
2-s2.0-85044056870
PubMed ID
Source
Asia-Pacific Journal of Ophthalmology
Sources of information:
Directorio de Producción Científica
Scopus